Renders Simon, Waclawiczek Alexander, Trumpp Andreas
Department of Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
Division of Stem Cells and Cancer, Deutsches Krebsforschungszentrum (DKFZ), DKFZ-ZMBH Alliance, Heidelberg, Germany.
Blood Cancer Discov. 2025 Sep 3;6(5):403-405. doi: 10.1158/2643-3230.BCD-25-0174.
In a large retrospective multicenter study of patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax, Lachowiez and colleagues examine the interplay among genetic mutations, disease phenotype, and clinical outcomes. They show that within genetic subgroups-particularly NPM1 wild-type cases-monocytic differentiation is linked to poor treatment response and inferior long-term prognosis, adding a phenotypic layer to genetics-based response prediction. See related article by Lachowiez et al., p. 437.
在一项针对接受去甲基化药物和维奈克拉治疗的急性髓系白血病患者的大型回顾性多中心研究中，拉乔维茨及其同事研究了基因突变、疾病表型和临床结果之间的相互作用。他们发现，在基因亚组中，尤其是NPM1野生型病例中，单核细胞分化与治疗反应不佳和长期预后较差有关，这为基于基因的反应预测增加了一个表型层面。见拉乔维茨等人的相关文章，第437页。
